特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 7月1日，原颇尔全球副总裁兼中国区总经理陈淮（Andy）正式出任贝克曼库尔特医学诊断全球副总裁兼中国区总经 理。 与此同时，原贝克曼库尔特临床诊断全球副总裁、中国区总经理陈 小穗（Rosa Chen）将全面聚焦丹纳赫中国医学诊 断平台的整体运营管理工作，继 续担任平台总裁职务。 陈淮将直接向陈小穗汇报，同时强虚线汇报给贝克曼库尔特医学诊断全球总裁Kev in O'Rei l y。 陈淮 2019年5月加入丹纳赫，拥有丰富的跨行业管理经验。在加入丹纳赫之前，他曾在精密制造领域领先企业梅特勒-托利 多担任多个关键管理职位，涵盖销售、市场营销及高级总经理等职务。他毕业于南京理工大学，拥有中欧国际工商学院 MBA学位。 | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号立 场 | 转 载 ： 须 本 号 授 权 ， 请 联 系 主 编 | 来 源 ： 互 联 网 仪 器 信 息 网 | 责 编 ： 满 ...

Danaher (NYSE: DHR ) should see good growth moving forward. Its Biotech segment is seeing good momentum, driven by double-digit growth in consumables. Equipment orders are also starting to bounce back, and I expect equipment revenues to return to growth, furtherWe focus on GARP (Growth at reasonable Price) opportunities in industrial, consumer, and technology sectors. We are among the top 50 financial experts (Out of ~39,000 tracked) as measured by Tipranks based on the consistency of our stock recommendati ...

Core Viewpoint - Danaher Corporation is enhancing its digital transformation by appointing Martin Stumpe as Chief Technology and AI Officer, effective October 1, 2025, to lead the integration of AI across its global businesses [1][2][3]. Group 1: Appointment and Leadership - Martin Stumpe will report directly to Rainer Blair, President and CEO, marking a significant step in Danaher's ambition to lead innovation in life sciences and diagnostics [1][2]. - Stumpe's previous experience includes serving as Chief Data and AI Officer at Tempus and founding the Cancer Pathology project at Google, showcasing his expertise in AI and healthcare [3]. Group 2: Strategic Goals - Under Stumpe's leadership, Danaher aims to accelerate the integration of AI, enhancing scientific discovery, operational efficiency, and clinical impact [2][3]. - The company is committed to leveraging science, data, and technology to improve human health, emphasizing the importance of innovation in addressing health challenges globally [3][4]. Group 3: Company Overview - Danaher is recognized as a leading global innovator in life sciences and diagnostics, with a workforce of 63,000 associates dedicated to improving quality of life and developing life-changing therapies [4]. - The company focuses on scientific excellence and continuous improvement to enable faster and more accurate diagnoses, ultimately reducing the time and cost of therapy development [4].

Core Viewpoint - Danaher Corporation has appointed Greg Milosevich as Executive Vice President responsible for its Life Sciences business, effective July 1, 2025, highlighting the company's commitment to leadership continuity and growth in this sector [1][2]. Company Overview - Danaher Corporation is a leading global innovator in life sciences and diagnostics, focused on improving human health through advanced science and technology [4]. - The company employs approximately 63,000 associates worldwide, dedicated to solving significant health challenges and enhancing the quality of life for billions of people [4]. Leadership Appointment - Greg Milosevich has been with Danaher since 2010 and has held various roles, most recently as Vice President and Group Executive of the Life Sciences Innovations Group since 2021 [2][3]. - His appointment as Executive Vice President is seen as a strategic move to leverage his experience and results-driven approach to further advance Danaher's Life Sciences business [3]. Business Impact - Milosevich's leadership is expected to drive continued success in the Life Sciences sector, which includes overseeing multiple Danaher companies such as Beckman Coulter Life Sciences and Sciex [3].

导读： 2024年全球科学仪器公司CEO薪酬榜单发布，赛默飞CEO以超2亿元薪酬登顶，行业整体净利润 下滑，高管薪酬与业绩挂钩成关注焦点。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 又是一年一度"年报季"！我们推出了"2024年全球上市仪器公司财报解读"专题。 随着2024年报季落幕，一众科学仪器上市公司陆续交出上一年度业绩"成绩单"。过去一年， 行业整体承压，国际形势复杂、竞争加剧，企业利润收窄、成本攀升，降薪裁员、架构调整成 为普遍现象。在行业普遍降本增效的背景下，跨国仪器企业CEO的薪酬表现如何？仪器信息网 特此整理"2024年跨国仪器公司CEO薪酬榜"，为您揭晓。 | | | | | | 2024年13家跨国仪器企业CEO薪酬榜 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | Summary Compensation | | | | | | | CEO 薪酬 農新 | 2023 排名 | 企 ...

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores serve as complementary indicators to the Zacks Rank, helping investors select stocks with high potential for market outperformance [2] Zacks Style Scores Overview - Stocks are rated from A to F based on value, growth, and momentum qualities, with A being the highest score indicating better chances of outperforming the market [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - Focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - Concentrates on a company's financial health and future growth potential, analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - Targets stocks experiencing upward or downward trends, utilizing metrics like one-week price change and monthly earnings estimate changes [5] VGM Score - Combines the three Style Scores to identify stocks with attractive value, strong growth forecasts, and promising momentum [6] Zacks Rank Integration - The Zacks Rank is a proprietary model based on earnings estimate revisions, aiding investors in building successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41%, significantly outperforming the S&P 500 [8] Stock Selection Strategy - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [10] - Stocks with lower ranks, even with high Style Scores, may still face downward price trends [11] Company Spotlight: Danaher Corporation - Danaher Corporation is a global conglomerate with a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating potential for growth investors [12] - The company has seen upward revisions in earnings estimates, with a Zacks Consensus Estimate of $7.70 per share for fiscal 2025 and an average earnings surprise of 8.5% [13]

Group 1 - Danaher (NYSE: DHR) is considered an excellent long-term investment opportunity with reported returns on equity (ROEs) above 7.8% [1] - The company has a strong focus on financial analysis and investment strategies, particularly in sectors such as commodities, banking, technology, and pharmaceuticals [1]

Core Points - Danaher Corporation will host its quarterly earnings conference call for Q2 2025 on July 22, 2025, at 8:00 a.m. ET, lasting approximately one hour [1] - The call will cover financial performance and future expectations, with a slide presentation available on Danaher's website [2] - A replay of the call will be accessible shortly after its conclusion until August 5, 2025 [3] Company Overview - Danaher is a global leader in life sciences and diagnostics, focused on improving human health through science and technology [4] - The company collaborates with customers to address significant health challenges, enabling faster and more accurate diagnoses [4] - With around 63,000 associates worldwide, Danaher aims to enhance quality of life for billions while laying the groundwork for a sustainable future [4]

Core Insights - CVS Health is currently rated 2 (Buy) while Danaher is rated 3 (Hold), indicating a more favorable earnings estimate revision activity for CVS [3] - Value investors assess a range of traditional metrics to determine if a company is undervalued at its current share price [3] Valuation Metrics - CVS has a forward P/E ratio of 10.54 compared to Danaher's 26.32, suggesting CVS is more attractively priced [5] - CVS's PEG ratio is 0.92, while Danaher's PEG ratio is 2.84, indicating CVS has a better growth-adjusted valuation [5] - CVS's P/B ratio stands at 1.05, significantly lower than Danaher's P/B ratio of 2.85, further supporting CVS's valuation advantage [6] - CVS's overall Value grade is A, while Danaher's Value grade is D, highlighting CVS's superior valuation metrics and earnings outlook [6]

Danaher Corporation (DHR) recently partnered with AstraZeneca PLC (AZN) to develop and market novel diagnostic tools aimed at improving patient selection for precision medicine treatments.Based in Cambridge, UK, AstraZeneca is a biopharmaceutical company that researches, develops, manufactures and commercializes innovative prescription medicines. The company works with primary and specialty care doctors through distributors and representative offices in the US, the UK, Europe and Asia.Inside the HeadlinesPr ...